Skip to main content

Advertisement

Table 1 Characteristics of studies included in the meta-analysis

From: Prognostic role of myeloid-derived suppressor cells in cancers: a systematic review and meta-analysis

Study Year Country Sample size Cancer types Phenotype Cut-off Age Follow-up (month) NOS scores Survival analysis
Zhang, Y 2017 China 76 rectal carcinoma HLA-DRCD33+CD11b+ 3.68 NA NA 5 OS
Yang, G 2017 China 113 bladder cancer HLA-DRCD33lowCD11b+CD3 21 66.5 (45–84) 43 (4–60) 6 OS
Gao, X.H 2017 China 183 HCC HLA-DR-/lowCD14 2.31 NA 24 (1.3–28.8) 6 OS, RFS
Wang, D1 2016 China 92 HCC HLA-DR-/lowCD14 14.6 NA NA 6 OS
Wang, D2 2016 China 92 HCC HLA-DR-/lowCD14 14.6 NA NA 6 OS
Choi, H.S 2016 Korea 28 GC HLA-DRCD11b+CD14+CD45+ 2.2 37–88 29 (10–42) 8 OS, DFS
Zhang, H1 2015 China 32 NK/T lymphoma HLA-DRCD33+CD11b+ 1.1 40.5 (17–70) 52 7 OS, DFS
Zhang, H2 2015 China 32 NK/T lymphoma HLA-DRCD33+CD11b+CD14+ 0.7 NA NA 7 OS, DFS
Yuan, L1 2015 China 64 rectal carcinoma LinHLA-DRCD33+CD11b+ 3.78 62 (38–76) 72 5 OS
Yuan, L2 2015 China 64 rectal carcinoma LinHLA-DRCD33+CD11b+ 2.11 NA NA 5 OS
Tian, T 2015 China 42 small-cell lung cancer HLA-DR-/lowCD14 21.7 62.4 36 6 OS
Jiang, H 2015 Germany 51 advanced melanoma HLA-DRCD11b+CD14+CD15 2.3 61.26 (33–88) 7 8 OS
Huang, H 2015 China 78 ESCC HLA-DR-/lowCD14 2.38 62.4 (46–77) 42 7 OS
Chevolet, I 2015 Belgium 69 melanoma LinHLA-DRCD33+CD11b+ 4.13 NA 39 7 OS
Weide, B 2014 Australia 94 advanced melanoma HLA-DR-/lowCD11b+CD14+ 11 NA 15 9 OS
Wang, L 2013 Singapore 40 GC LinHLA-DRCD33+ 4 NA NA 7 OS
Arihara, F1 2013 Japan 123 HCC HLA-DR-/lowCD14 22 NA NA 7 RFS-U
Arihara, F2 2013 Japan 123 HCC HLA-DR-/lowCD14 22 NA NA 7 RFS-U, RFS-M
Solito, S1 2011 Italy 25 colorectal cancer LinHLA-DRCD33+CD11b+ 2.54 NA NA 9 OS
Solito, S2 2011 Italy 26 bresat cancer LinHLA-DRCD33+CD11b+ 3.17 NA NA 9 OS
Gabitass, R.F 2011 UK 256 pancreatic, esophageal and gastric cancer Linlow/-HLA-DRCD33+CD11b+ 2 NA NA 7 OS
  1. HCC hepatocelluar carcinoma, GC gastric cancer, ESCC esophageal squamous cell carcinoma
  2. NA not applicable, NOS the Newcastle–Ottawa Quality Assessment Scale
  3. OS overall survival, DFS disease-free survival, RFS recurrence-free survival, U&M univariate & multivariate survival analysis